|
AU2009239437B2
(en)
*
|
2008-04-25 |
2014-11-13 |
University Of Washington |
Levels of BCMA protein expression on B cells and use in diagnostic methods
|
|
EP2640750A1
(en)
*
|
2010-11-16 |
2013-09-25 |
Boehringer Ingelheim International GmbH |
Agents and methods for treating diseases that correlate with bcma expression
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
SI3415531T1
(sl)
*
|
2011-05-27 |
2023-12-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezni proteini
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
TWI679212B
(zh)
*
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
AU2013246443B2
(en)
|
2012-04-11 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
JP6694712B2
(ja)
*
|
2012-11-01 |
2020-05-20 |
マックス−デルブルック−セントラム フアー モレキュラーレ メデジン |
Ｃｄ２６９（ｂｃｍａ）に対する抗体
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
|
EP2954330A4
(en)
|
2013-02-08 |
2016-08-31 |
Inst Myeloma & Bone Cancer Res |
IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MULTIPLE MYELOMA, CHRONIC LYMPHATIC LEUKEMIA AND NON-HODGKIN B CELL LYMPHOMA
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
AR095374A1
(es)
*
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
JP6752148B2
(ja)
|
2014-02-07 |
2020-09-09 |
マクマスター ユニバーシティー |
三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用
|
|
JP6825910B2
(ja)
|
2014-03-26 |
2021-02-03 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） |
Ｆｌａｔｔｏｐ（Ｆｌｔｐ）はβ細胞成熟についての新規のバイオマーカーである
|
|
RS62733B1
(sr)
|
2014-04-25 |
2022-01-31 |
2Seventy Bio Inc |
Mnd promoter himernih antigenskih receptora
|
|
JP6817069B2
(ja)
|
2014-04-25 |
2021-01-20 |
ブルーバード バイオ， インコーポレイテッド |
養子細胞療法薬を製造するための改善された方法
|
|
KR102632731B1
(ko)
*
|
2014-04-30 |
2024-02-01 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
SG10201810723VA
(en)
|
2014-06-06 |
2018-12-28 |
Bluebird Bio Inc |
Improved t cell compositions
|
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
|
RU2711141C2
(ru)
|
2014-07-22 |
2020-01-15 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Антитела против pd-1
|
|
ES2878449T3
(es)
*
|
2014-07-24 |
2021-11-18 |
2Seventy Bio Inc |
Receptores antigénicos quiméricos de BCMA
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
WO2016022630A1
(en)
|
2014-08-05 |
2016-02-11 |
Jiping Zha |
Anti-pd-l1 antibodies
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
CA2969870A1
(en)
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
AU2015357533B2
(en)
*
|
2014-12-05 |
2021-10-07 |
Eureka Therapeutics, Inc. |
Antibodies targeting B-cell maturation antigen and methods of use
|
|
RS62527B1
(sr)
|
2014-12-12 |
2021-11-30 |
2Seventy Bio Inc |
Bcma receptori himernog antigena
|
|
SG10201912823PA
(en)
*
|
2015-04-13 |
2020-02-27 |
Pfizer |
Therapeutic antibodies and their uses
|
|
PE20171653A1
(es)
|
2015-04-13 |
2017-11-13 |
Pfizer |
Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
|
|
EP3466967A1
(en)
*
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR20180033232A
(ko)
*
|
2015-07-24 |
2018-04-02 |
온코트랙커 인코포레이티드 |
면역계 기능장애의 치료를 위한 감마 세크레타제 조절제
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
RS60030B1
(sr)
*
|
2015-08-03 |
2020-04-30 |
Engmab Sarl |
Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
|
|
CN108350076B
(zh)
|
2015-08-17 |
2022-06-07 |
詹森药业有限公司 |
抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
|
|
HK1258726A1
(zh)
|
2015-09-28 |
2019-11-15 |
Regents Of The University Of Minnesota |
嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
|
|
CA3005042A1
(en)
*
|
2015-11-13 |
2017-05-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-bcma polypeptides and proteins
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
EP3402515B8
(en)
*
|
2016-01-12 |
2021-12-08 |
Oncotracker, Inc. |
Improved methods for monitoring immune status of a subject
|
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
CN116063544A
(zh)
|
2016-02-03 |
2023-05-05 |
安进研发（慕尼黑）股份有限公司 |
Bcma和cd3双特异性t细胞接合抗体构建体
|
|
US20190194338A1
(en)
*
|
2016-02-17 |
2019-06-27 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
AU2017233121B2
(en)
|
2016-03-15 |
2023-12-21 |
Itabmed (Hk) Limited |
Multispecific Fab fusion proteins and use thereof
|
|
WO2017173256A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
|
PE20190120A1
(es)
|
2016-04-01 |
2019-01-17 |
Kite Pharma Inc |
Moleculas de union a bcma y metodos de uso de las mismas
|
|
KR102120815B1
(ko)
|
2016-04-01 |
2020-06-12 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
EP3471773A4
(en)
|
2016-06-21 |
2020-07-08 |
Teneobio, Inc. |
ANTIBODIES BINDING CD3
|
|
US11242376B2
(en)
|
2016-08-02 |
2022-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CN117603353A
(zh)
|
2016-09-14 |
2024-02-27 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
GB2564823B8
(en)
|
2016-10-07 |
2022-06-29 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
CN110022906A
(zh)
|
2016-11-04 |
2019-07-16 |
蓝鸟生物公司 |
抗bcma car t细胞组合物
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018119215A1
(en)
*
|
2016-12-21 |
2018-06-28 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
JP7115758B2
(ja)
|
2017-02-28 |
2022-08-09 |
アッフィメッド・ゲー・エム・ベー・ハー |
Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
|
|
CN110475790A
(zh)
|
2017-03-24 |
2019-11-19 |
全药工业株式会社 |
抗IgM/B细胞表面抗原双特异性抗体
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3618842B1
(en)
|
2017-05-01 |
2023-10-18 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
EP3639028B1
(en)
|
2017-06-13 |
2025-10-15 |
Onco Tracker, Inc. |
Diagnostic, prognostic, and monitoring methods for breast cancer
|
|
JP2020523383A
(ja)
|
2017-06-14 |
2020-08-06 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
|
|
BR112019026907A2
(pt)
|
2017-06-20 |
2020-06-30 |
Teneobio, Inc. |
Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos
|
|
AU2018288803B2
(en)
|
2017-06-20 |
2025-02-27 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
KR20250009550A
(ko)
*
|
2017-08-01 |
2025-01-17 |
메디뮨 엘엘씨 |
Bcma 단클론 항체-약물 접합체
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
US20200207867A1
(en)
|
2017-09-13 |
2020-07-02 |
Teneobio, Inc. |
Heavy chain antibodies binding to ectoenzymes
|
|
WO2019066435A2
(ko)
*
|
2017-09-29 |
2019-04-04 |
재단법인 목암생명과학연구소 |
Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
JP7233425B2
(ja)
|
2017-11-06 |
2023-03-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法とガンマセクレターゼ阻害剤との組み合わせ
|
|
WO2019099639A1
(en)
|
2017-11-15 |
2019-05-23 |
Navartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
|
MA51105A
(fr)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics Inc |
Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
|
|
PE20201171A1
(es)
|
2017-12-22 |
2020-10-28 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
PL3674328T3
(pl)
|
2018-02-01 |
2024-09-16 |
Nanjing IASO Biotechnology Co., Ltd. |
Chimeryczny receptor antygenu (car) wiążący się z bcma i jego zastosowania
|
|
US11266690B2
(en)
|
2018-02-01 |
2022-03-08 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
|
|
CA3081125C
(en)
*
|
2018-02-01 |
2025-09-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
All-Human Single-Chain Variable Fragment Anti-Antigen for B Lymphocyte Maturation (BCMA), and Associated Application
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
AU2019228128A1
(en)
|
2018-03-02 |
2020-09-03 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
AU2019232759A1
(en)
*
|
2018-03-08 |
2020-08-27 |
Phanes Therapeutics, Inc. |
Anti-TIP-1 antibodies and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
MX2020010728A
(es)
|
2018-04-13 |
2020-11-06 |
Affimed Gmbh |
Constructos de fusion de anticuerpos que se acoplan a celulas nk.
|
|
CN120285175A
(zh)
|
2018-05-16 |
2025-07-11 |
詹森生物科技公司 |
治疗癌症并增强t细胞重定向治疗剂的功效的方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
WO2020004937A1
(ko)
*
|
2018-06-26 |
2020-01-02 |
주식회사 티에스디라이프사이언스 |
항-bcma 항체-약물 접합체 및 그 용도
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
CN119954969A
(zh)
|
2018-07-19 |
2025-05-09 |
瑞泽恩制药公司 |
具有bcma特异性的嵌合抗原受体及其用途
|
|
MX2021000708A
(es)
|
2018-07-20 |
2021-03-25 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al cd19.
|
|
IL280659B2
(en)
|
2018-08-09 |
2024-11-01 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
|
BR112021002245A2
(pt)
|
2018-08-09 |
2021-05-04 |
Juno Therapeutics Inc |
métodos para avaliar ácidos nucleicos integrados
|
|
WO2020034081A1
(en)
*
|
2018-08-14 |
2020-02-20 |
Hrain Biotechnology Co., Ltd. |
Bcma-targeting chimeric antigen receptor and uses thereof
|
|
HRP20251135T1
(hr)
|
2018-08-31 |
2025-11-21 |
Novartis Ag |
Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN112867735B
(zh)
|
2018-09-07 |
2025-05-09 |
埃泰美德(香港)有限公司 |
双特异性抗原结合蛋白及其用途
|
|
MX2021004732A
(es)
|
2018-10-26 |
2021-06-04 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd38.
|
|
EP3874024A1
(en)
|
2018-10-31 |
2021-09-08 |
Juno Therapeutics GmbH |
Methods for selection and stimulation of cells and apparatus for same
|
|
WO2020092848A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
US12263190B2
(en)
|
2018-11-08 |
2025-04-01 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
|
SG11202009283QA
(en)
|
2019-01-16 |
2020-10-29 |
Caribou Biosciences Inc |
Humanized bcma antibody and bcma-car-t cells
|
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
US20220202864A1
(en)
|
2019-05-07 |
2022-06-30 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Bcma-targeting engineered immune cell and use thereof
|
|
AU2020270298A1
(en)
|
2019-05-07 |
2021-12-23 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cell targeting BCMA and use thereof
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
CN113874398B
(zh)
|
2019-05-21 |
2025-08-01 |
诺华股份有限公司 |
Cd19结合分子及其用途
|
|
UA128906C2
(uk)
|
2019-06-14 |
2024-11-20 |
Тенеобіо, Інк. |
Поліспецифічні антитіла, що містять тільки важкі ланцюги, які зв'язуються з cd22 та cd3
|
|
CA3146341A1
(en)
|
2019-07-30 |
2021-02-04 |
Aaron L. Kurtzman |
Bispecific anti lrrc15 and cd3epsilun antibudies
|
|
CN112585168B
(zh)
*
|
2019-07-30 |
2022-04-15 |
上海翰森生物医药科技有限公司 |
抗bcma抗体、其抗原结合片段及其医药用途
|
|
CN112409482B
(zh)
*
|
2019-08-20 |
2022-08-26 |
杭州尚健生物技术有限公司 |
Bcma抗体
|
|
WO2021051390A1
(zh)
*
|
2019-09-20 |
2021-03-25 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
WO2021132746A1
(en)
*
|
2019-12-24 |
2021-07-01 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
CN115023441A
(zh)
|
2019-12-18 |
2022-09-06 |
特诺福尔股份有限公司 |
与cd38结合的重链抗体
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
KR20220012314A
(ko)
*
|
2020-01-03 |
2022-02-03 |
살루브리스 (청두) 바이오테크 코., 리미티드 |
Bcma에 결합하는 항체 및 그의 용도
|
|
CA3166420A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
|
MX2022008771A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Metodos y composiciones de muteinas de il2 sesgadas.
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
CN113248611B
(zh)
*
|
2020-02-13 |
2026-02-06 |
上海泰槿生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
TW202146441A
(zh)
|
2020-02-27 |
2021-12-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
|
CN116157125A
(zh)
|
2020-04-28 |
2023-05-23 |
朱诺治疗学股份有限公司 |
针对bcma的t细胞疗法与免疫调节化合物的组合
|
|
CA3214992A1
(en)
|
2020-04-29 |
2021-11-04 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
KR20230005179A
(ko)
|
2020-04-29 |
2023-01-09 |
테네오바이오, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
AU2021272291A1
(en)
|
2020-05-11 |
2023-02-02 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
BR112022027101A2
(pt)
|
2020-06-30 |
2023-03-14 |
Teneobio Inc |
Anticorpos multiespecíficos que se ligam a bcma
|
|
CN115715298A
(zh)
*
|
2020-07-06 |
2023-02-24 |
四川科伦博泰生物医药股份有限公司 |
靶向bcma和cd19的嵌合抗原受体car或car构建体及其应用
|
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
JP2023539453A
(ja)
*
|
2020-08-20 |
2023-09-14 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
|
|
IL300489A
(en)
|
2020-08-21 |
2023-04-01 |
Novartis Ag |
Compositions and methods for in vivo production of CAR expressing cells
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
US20240084014A1
(en)
|
2020-10-16 |
2024-03-14 |
Qlsf Biotherapeutics, Inc. |
Multispecific binding compounds that bind to pd-l1
|
|
WO2022094245A1
(en)
|
2020-10-30 |
2022-05-05 |
Vor Biopharma, Inc. |
Compositions and methods for bcma modification
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
|
CN113173991B
(zh)
*
|
2020-12-31 |
2023-03-28 |
北京艺妙神州医药科技有限公司 |
一种抗bcma的抗体及其应用
|
|
JP2024501971A
(ja)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃａｒ－ｔ活性を調節するための方法及び組成物
|
|
AU2022206324A1
(en)
|
2021-01-11 |
2023-07-20 |
Sana Biotechnology, Inc. |
Use of cd8-targeted viral vectors
|
|
CN117279953A
(zh)
|
2021-02-16 |
2023-12-22 |
詹森药业有限公司 |
靶向bcma、gprc5d和cd3的三特异性抗体
|
|
EP4298130A2
(en)
|
2021-02-25 |
2024-01-03 |
Teneobio, Inc. |
Anti-psma antibodies and car-t structures
|
|
AU2022226565A1
(en)
|
2021-02-26 |
2023-08-31 |
Teneobio, Inc. |
Anti-muc1-c antibodies and car-t structures
|
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
|
|
EP4310188A1
(en)
|
2021-03-17 |
2024-01-24 |
Daiichi Sankyo Company, Limited |
Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
|
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
KR20230158573A
(ko)
|
2021-03-22 |
2023-11-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
바이러스 벡터 입자의 효력을 평가하는 방법
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
JP2024514107A
(ja)
|
2021-04-06 |
2024-03-28 |
テネオバイオ， インコーポレイテッド |
抗ｃｄ１９抗体及びｃａｒ－ｔ構造体
|
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
|
JP2024514163A
(ja)
|
2021-04-16 |
2024-03-28 |
セルジーン コーポレーション |
Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
|
|
IL307598A
(en)
|
2021-04-16 |
2023-12-01 |
Juno Therapeutics Inc |
T-cell therapy in patients who have had a previous stem cell transplant
|
|
AU2022259688A1
(en)
|
2021-04-16 |
2023-10-05 |
Teneobio, Inc. |
Anti-cd20 antibodies and car-t structures
|
|
AU2022267891A1
(en)
|
2021-04-27 |
2023-11-09 |
Novartis Ag |
Viral vector production system
|
|
US20250283037A1
(en)
|
2021-05-06 |
2025-09-11 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
US20240252642A1
(en)
|
2021-05-19 |
2024-08-01 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
|
WO2022251367A1
(en)
|
2021-05-27 |
2022-12-01 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
CA3173810A1
(en)
|
2021-06-01 |
2022-12-01 |
Andreas Bader |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
|
WO2023287827A2
(en)
|
2021-07-14 |
2023-01-19 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
US20240342215A1
(en)
|
2021-07-14 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
|
JP2024528981A
(ja)
|
2021-08-04 |
2024-08-01 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ４標的化ウイルスベクターの使用
|
|
EP4384188A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
CA3229746A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
IL312043A
(en)
|
2021-10-14 |
2024-06-01 |
Teneobio Inc |
Mesothelin binding proteins and their uses
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
JP2024540054A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
癌を治療する方法及びｂｃｍａ×ｃｄ３二重特異性抗体の有効性を向上させる方法
|
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
KR20240137574A
(ko)
|
2021-12-23 |
2024-09-20 |
사나 바이오테크놀로지, 인크. |
자가면역 질환 치료를 위한 키메라 항원 수용체[chimeric antigen receptor, car] t 세포 및 관련 방법
|
|
CN114276452A
(zh)
*
|
2021-12-29 |
2022-04-05 |
源道隆（苏州）医学科技有限公司 |
可结合bcma的纳米抗体及其应用
|
|
AU2022423984A1
(en)
|
2021-12-30 |
2024-08-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
IL314843A
(en)
|
2022-02-09 |
2024-10-01 |
Hadasit Med Res Service |
Anti-bcma car to target immune-related disorders, compositions and method thereof
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
AU2023251117A1
(en)
|
2022-04-08 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Multipartite receptor and signaling complexes
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
CN120051297A
(zh)
|
2022-06-30 |
2025-05-27 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
|
|
EP4561613A1
(en)
|
2022-07-27 |
2025-06-04 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
US20260027145A1
(en)
|
2022-07-27 |
2026-01-29 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
EP4311579A1
(en)
*
|
2022-07-29 |
2024-01-31 |
Association Française contre les Myopathies |
B cell-specific mab-sirna conjugates improve myasthenia
|
|
CA3263560A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
EP4590688A1
(en)
|
2022-09-21 |
2025-07-30 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
JP2025535042A
(ja)
|
2022-10-05 |
2025-10-22 |
アムジェン インコーポレイテッド |
Ｔ細胞リダイレクト療法及びアゴニスト抗ｉｌ－２ｒ抗体又はその断片を含む組み合わせ療法
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
WO2024178056A1
(en)
|
2023-02-21 |
2024-08-29 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
|
WO2024206329A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
WO2024220256A1
(en)
|
2023-04-18 |
2024-10-24 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to ly6g6d
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
CN121443743A
(zh)
|
2023-05-23 |
2026-01-30 |
赛纳生物技术公司 |
串联融合剂和相关脂质颗粒
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025096878A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics, Inc. |
Rna for in vivo transfection with increased expression
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025109119A1
(en)
|
2023-11-22 |
2025-05-30 |
Priothera Sas |
Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
|
|
US20250332281A2
(en)
|
2023-12-15 |
2025-10-30 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025217101A2
(en)
|
2024-04-09 |
2025-10-16 |
Amgen Inc. |
Agonistic anti-il-2rbg heavy‑chain antibodies
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
TW202544034A
(zh)
|
2024-05-06 |
2025-11-16 |
美商榮都醫療公司 |
結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
|
|
WO2026006767A1
(en)
|
2024-06-28 |
2026-01-02 |
Dispatch Biotherapeutics, Inc. |
Tethered il-9/il-9r and related engineered cells and methods
|
|
WO2026015450A1
(en)
|
2024-07-06 |
2026-01-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|